Related articles
Back to basics: Agentic AI and how it’s impacting clinical trial research
Since the release of OpenAI’s ChatGPT in 2022, the buzz around artificial intelligence has been impossible to ignore. From advertisements during the SuperBowl to webinars and working groups, the impact of artificial intelligence has been felt in almost every sector of our world.
But, what if we told you the most transformative shift is still on the horizon?
When ChatGPT first released it changed the way the world, including clinical research, worked. Now NVIDIA, one of the most premier companies leading the way in the development of AI, has stated that they expect the development of Agentic AI, a new type of artificial intelligence to “change the way we work in ways that parallel how different work became with the arrival of the internet.”
This means agentic AI may have a much bigger impact than even generative AI did years back.
So, if you’re curious about agentic AI, read on as we delve into its nature, differentiate it from generative AI, and reveal its transformative role in clinical research."
The Top 5 myths about eCOA in 2025
With MarketsandMarkets projecting the global electronic Clinical Outcome Assessments (eCOA) solutions market to grow at compound annual growth rate (CAGR) of 16.1% each year until 2030, it’s clear the eCOA has made its impact within the clinical research landscape.
Yet despite growing adoption, electronic Clinical Outcome Assessments (eCOA) are still surrounded by misconceptions that hinder their full potential. From concerns about patient usability to assumptions about cost and implementation timelines, these myths can create hesitation among sponsors and research teams alike.
Thus, we’re here to cut through the noise and set the record straight with a summary of a recent webinar featuring speakers from Transcelerate and Medable.
What happened at ASCO 2025?
2025’s American Society of Clinical Oncology (ASCO) meeting in Chicago once again delivered a wealth of clinical data, providing exciting insights into the groundbreaking future of cancer treatment. As the show closed out, we checked in with our associates to see what they thought were the biggest news and trends of the show.